CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
rhPSMA-7.3 (18F) Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03995888
NCT03995888Phase 1Completed
CompareCT.gov

A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects With Prostate Cancer

Blue Earth Diagnostics·interventional·Posted Jun 24, 2019·Updated Feb 12, 2026

In Brief

A Phase 1 clinical trial evaluating rhPSMA-7.3 (18F) Injection for Prostate Cancer. Completed, enrolled 24 participants across 1 site.

Detailed Summary

A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects With Prostate Cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesFinland
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJun 24, 2019
Enrollment StartJun 11, 2019
Primary CompletionApr 16, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 7.0 years ago

Interventions

rhPSMA-7.3 (18F) Injectiondrug

Radioligand for PET CT scanning